Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.74−0.06 (-7.79%)
Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%
Allogene Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Allogene Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $114.09M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $22.00K | -76.8% |
| FY2023 | Dec 31, 2023 | $95.00K | -39.1% |
| FY2022 | Dec 31, 2022 | $156.00K | -99.9% |
| FY2021 | Dec 31, 2021 | $114.09M | – |
| FY2020 | Dec 31, 2020 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.64M | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $22.00K | -26.7% |
| Q4 FY2023 | Dec 31, 2023 | $21.00K | -19.2% |
| Q3 FY2023 | Sep 30, 2023 | $22.00K | -18.5% |
| Q2 FY2023 | Jun 30, 2023 | $22.00K | -65.6% |
| Q1 FY2023 | Mar 31, 2023 | $30.00K | -23.1% |
| Q4 FY2022 | Dec 31, 2022 | $26.00K | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $27.00K | -44.9% |
| Q2 FY2022 | Jun 30, 2022 | $64.00K | +45.5% |
| Q1 FY2022 | Mar 31, 2022 | $39.00K | -99.9% |
| Q4 FY2021 | Dec 31, 2021 | $75.65M | – |
| Q3 FY2021 | Sep 30, 2021 | $49.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $44.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $38.35M | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
See a number that looks wrong?